SCHEMBL2878010

SCHEMBL2878010

COC(=O)C(=O)c1c(-c2ccc(Cl)c(S(=O)(=O)NC3CCCCC3)c2)[nH]c2cccc(C)c12

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 10/20 0.45
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
TP53 P04637 3/20 0.39
PKM P14618 1/20 0.39
ALOX15 P16050 1/20 0.39
BRD3 Q15059 3/20 0.38
BRD2 P25440 2/20 0.38
PI4KB Q9UBF8 1/20 0.38
HTT P42858 1/20 0.38
MAPK1 P28482 1/20 0.38
CASP1 P29466 1/20 0.38
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2875790 0.93 BRD4 (0.46) BRD4ALDH1A1SMN1; SMN2MEN1LMNA
SCHEMBL27751386 0.91 BRD4 (0.46) BRD4ALDH1A1SMN1; SMN2MEN1LMNA
SCHEMBL2878374 0.91 BRD4 (0.44) BRD4ALDH1A1SMN1; SMN2MEN1LMNA
SCHEMBL4000392 0.90 BRD4 (0.48) BRD4ALDH1A1SMN1; SMN2MEN1LMNA
SCHEMBL2875900 0.88 BRD4 (0.48) BRD4ALDH1A1SMN1; SMN2MEN1LMNA
SCHEMBL2873159 0.87 BRD4 (0.44) BRD4ALDH1A1SMN1; SMN2MEN1LMNA
SCHEMBL2876533 0.85 BRD4 (0.44) BRD4ALDH1A1SMN1; SMN2MEN1LMNA
SCHEMBL2875004 0.84 BRD4 (0.46) BRD4ALDH1A1SMN1; SMN2MEN1LMNA
SCHEMBL27772052 0.83 BRD4 (0.48) BRD4ALDH1A1SMN1; SMN2MEN1LMNA
SCHEMBL2877922 0.83 BRD4 (0.45) BRD4ALDH1A1SMN1; SMN2MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2066628-B1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS SANOFI AVENTIS (FR) 2010-10-20 EP disclosed
US-20090176804-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2009-07-09 US disclosed
EP-2066628-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS Sanofi-Aventis (FR) 2009-06-10 EP disclosed
WO-2008014186-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176804-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS PTGER2, PTGDR2, CYSLTR2 BRD4 1328/4885ALDH1A1 1757/4885SMN1; SMN2 3283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.